A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZabeen Mahuwala, MD
About this trial
Three pieces of information lead to the basis for this study:
1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin.
The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.
Eligibility criteria
Qualifiers
Subject has been diagnosed with Type-2 Diabetes.
Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.
Disqualifiers
Subject has not been diagnosed with Type-2 Diabetes.
Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Zabeen Mahuwala, MD
Lead sponsor
University of Kentucky
Sponsor institution
Source ClinicalTrials.gov